lenalidomide medical valley 5 mg kapsułki twarde
medical valley invest ab - lenalidomidum - kapsułki twarde - 5 mg
lenalidomide ranbaxy 5 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 5 mg
lenalidomide ranbaxy 25 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 25 mg
lenalidomide ranbaxy 7,5 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 7,5 mg
lenalidomide ranbaxy 10 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 10 mg
lenalidomide ranbaxy 20 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 20 mg
lenalidomide ranbaxy 15 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 15 mg
lenalidomide ranbaxy 2,5 mg kapsułki twarde
ranbaxy (poland) sp. z o.o. - lenalidomidum - kapsułki twarde - 2,5 mg
lenalidomide fresenius kabi 25 mg kapsułki twarde
fresenius kabi polska sp. z o.o. - lenalidomidum - kapsułki twarde - 25 mg
sarclisa
sanofi winthrop industrie - isatuximab - szpiczak mnogi - Środki przeciwnowotworowe - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.